Literature DB >> 22782135

The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.

Patrick K Davis, Harsha Musunuru, Mark Walsh, Raman Mitra, Victoria Ploplis, Francis J Castellino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22782135     DOI： 10.1160/TH12-04-0222

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  4 in total

1.  In vitro and ex vivo Measurement of Prophylactic Dabigatran Concentrations with a New Ecarin-Based Thromboelastometry Test.

Authors:  Mareike Kristina Körber; Elisabeth Langer; Martin Köhr; Klaus-Dieter Wernecke; Wolfgang Korte; Christian von Heymann
Journal:  Transfus Med Hemother       Date:  2017-03-27       Impact factor: 3.747

2.  Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.

Authors:  Jennifer L Aron; Robert Gosselin; Stephan Moll; Charles F Arkin; Simon Mantha
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

3.  Dabigatran excess: case report and review of the literature.

Authors:  Amy Sarma; Jeffrey E Rossi; Jean M Connors; Robert P Giugliano
Journal:  Cardiol Ther       Date:  2013-06-01

Review 4.  Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.

Authors:  Mark Walsh; Stephanie Fritz; Daniel Hake; Michael Son; Sarah Greve; Manar Jbara; Swetha Chitta; Braxton Fritz; Adam Miller; Mary K Bader; Jonathon McCollester; Sophia Binz; Alyson Liew-Spilger; Scott Thomas; Anton Crepinsek; Faisal Shariff; Victoria Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.